Search

Displaying results 5221 - 5230 of 10000 in total
  1. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Ruxolitinib Combinations in Myelofibrosis Patients). … Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

    Synonyms: 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluorobenzamide, Benzamide, 4-(3-amino-6-((1s,3s,4s)-3-fluoro-4-hydroxycyclohexyl)-2-pyrazinyl)-n-((1s)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl)-2-fluoro-
  2. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  3. Drug

    Sisunatovir

    go.drugbank.com/drugs/DB15674
    Investigational

    Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).

  4. Drug

    Apitegromab

    go.drugbank.com/drugs/DB16096
    Investigational

    Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).

  5. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. … Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]

  6. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  7. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

  8. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

    Synonyms: N-(α-pyridyl)-N-(α-thenyl)-N',N'-dimethylethylenediamine, N,N-dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine
  9. Drug

    DCLL-9718S

    go.drugbank.com/drugs/DB17392
    Investigational

    DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1).

  10. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.